Correlation Between Lumos Pharma and Theriva Biologics
Can any of the company-specific risk be diversified away by investing in both Lumos Pharma and Theriva Biologics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lumos Pharma and Theriva Biologics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lumos Pharma and Theriva Biologics, you can compare the effects of market volatilities on Lumos Pharma and Theriva Biologics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lumos Pharma with a short position of Theriva Biologics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lumos Pharma and Theriva Biologics.
Diversification Opportunities for Lumos Pharma and Theriva Biologics
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Lumos and Theriva is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Lumos Pharma and Theriva Biologics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Theriva Biologics and Lumos Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lumos Pharma are associated (or correlated) with Theriva Biologics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Theriva Biologics has no effect on the direction of Lumos Pharma i.e., Lumos Pharma and Theriva Biologics go up and down completely randomly.
Pair Corralation between Lumos Pharma and Theriva Biologics
If you would invest 115.00 in Theriva Biologics on December 19, 2024 and sell it today you would earn a total of 4.00 from holding Theriva Biologics or generate 3.48% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Flat |
Strength | Insignificant |
Accuracy | 0.0% |
Values | Daily Returns |
Lumos Pharma vs. Theriva Biologics
Performance |
Timeline |
Lumos Pharma |
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Theriva Biologics |
Lumos Pharma and Theriva Biologics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Lumos Pharma and Theriva Biologics
The main advantage of trading using opposite Lumos Pharma and Theriva Biologics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lumos Pharma position performs unexpectedly, Theriva Biologics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Theriva Biologics will offset losses from the drop in Theriva Biologics' long position.Lumos Pharma vs. Shattuck Labs | Lumos Pharma vs. Champions Oncology | Lumos Pharma vs. Century Therapeutics | Lumos Pharma vs. Silo Pharma |
Theriva Biologics vs. Avalo Therapeutics | Theriva Biologics vs. Virpax Pharmaceuticals | Theriva Biologics vs. Revelation Biosciences | Theriva Biologics vs. Biodexa Pharmaceticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Complementary Tools
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |